Our lab has already reported that Spry1 is a partner protein of the urokinase-type plasminogen activator receptor (uPAR)[21] which is able to inhibit uPAR-stimulated migration and invasion in the Saos-2 osteosarcoma, MDA-MB-231 breast cancer and HCT116 colorectal cancer cell lines[22]. This evidence concerns the gene SPRY1 and breast carcinoma.